We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Foliglurax Enters Phase II Trial for Treatment of Parkinson's Patients

News   Jul 10, 2017 | Original Story from Prexton Therapeutics

 
Prexton Therapeutic's Parkinson's Drug Candidate, Foliglurax, Enters Phase II Trial
 
 
 

RELATED ARTICLES

Interference with Estrogen Signaling Sends Bone Formation into Overdrive

News

Deleting a certain type of estrogen receptor in an area of the hypothalamus dramatically increased bone density and strength in female mice, opening up many therapeutic possibilities for improving women's health.

READ MORE

Now Anyone Can Tour the Fly Brain

News

A new fly-through of the fly brain allows anyone to whizz past neurons and visit any of the 40 million synapses where neurons touch neuron. It’s a super-resolution view of the complex network connections in the insect’s brain that underlie behaviors ranging from feeding to mating.

READ MORE

Infrared to Visible Light: A Novel Route to Photodynamic Therapy & Drug Development

News

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE